CCA
EBS icon

Catalyst Capital Advisors’s Emergent Biosolutions EBS Stock Holding History

Catalyst Capital Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12,000
Closed -$378K – 431
2016
Q3 		$378K Buy
+12,000
New +$349K 0.04% 212

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Catalyst Capital Advisors's EBS Position: Q4 2016 in Review

Catalyst Capital Advisors sold out of Emergent Biosolutions (EBS) in Q4 2016, closing a stake of 12,000 shares — an estimated $378K sold.

Catalyst Capital Advisors first reported a position in EBS in Q3 2016 and held it in 1 quarter. The position peaked at $378K in Q3 2016. 208 funds tracked by Wall St. Rank hold EBS as of Q4 2016.

  • Catalyst Capital Advisors reported no remaining Emergent Biosolutions position as of Q4 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 12,000 Emergent Biosolutions shares in Q4 2016, an estimated $378K.
  • Catalyst Capital Advisors first reported a position in Emergent Biosolutions in Q3 2016 and held it in 1 quarter.
  • Catalyst Capital Advisors's Emergent Biosolutions position peaked at $378K in Q3 2016.
  • 208 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2016.

Based on Catalyst Capital Advisors's 13F filing for Q4 2016, filed 8 Feb 2017.